Cargando…

Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): Contribution of genotype to cognitive developmental course

The natural history of cognitive growth in the neuronopathic form of Mucopolysaccharidosis type II (MPS II) is not well defined especially their patterns of development and decline. The ability to predict the developmental course of the neurologically impaired patient is necessary to assess treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Joo-Hyun, Okuyama, Torayuki, Shapiro, Elsa, Fukuhara, Yasuyuki, Kosuga, Motomichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394748/ https://www.ncbi.nlm.nih.gov/pubmed/32775211 http://dx.doi.org/10.1016/j.ymgmr.2020.100630

Ejemplares similares

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up
por: Furujo, Mahoko, et al.
Publicado: (2017)

The levels of urinary glycosaminoglycans of patients with attenuated and severe type of mucopolysaccharidosis II determined by liquid chromatography-tandem mass spectrometry
por: Mashima, Ryuichi, et al.
Publicado: (2016)

Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2020)

The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2019)

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data
por: Giugliani, Roberto, et al.
Publicado: (2021)

Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Grant, Nathan
Publicado: (2020)

A cDNA analysis disclosed the discordance of genotype-phenotype correlation in a patient with attenuated MPS II and a 76-base deletion in the gene for iduronate-2-sulfatase
por: Fukuhara, Yasuyuki, et al.
Publicado: (2020)

A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan
por: Fukuhara, Yasuyuki, et al.
Publicado: (2017)

Levels of enzyme activities in six lysosomal storage diseases in Japanese neonates determined by liquid chromatography-tandem mass spectrometry
por: Mashima, Ryuichi, et al.
Publicado: (2016)

Maternal uniparental disomy of chromosome 7 underlying argininosuccinic aciduria and Silver-Russell syndrome
por: Hattori, Atsushi, et al.
Publicado: (2022)

Normal early development in siblings with novel compound heterozygous variants in ASPM
por: Moriwaki, Taro, et al.
Publicado: (2020)

The second report on spondyloepimetaphyseal dysplasia, aggrecan type: a milder phenotype than originally reported
por: Fukuhara, Yasuyuki, et al.
Publicado: (2019)

Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase
por: Hogan, Melissa J., et al.
Publicado: (2020)

A rare case of mucopolysaccharidosis: Hunter syndrome
por: Gajula, Prathima, et al.
Publicado: (2012)

A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT
por: Yee, Karen S., et al.
Publicado: (2023)

Progression of Left Ventricular Fibrosis in a Woman with Anderson-Fabry Disease: Longitudinal Observations Using Two-Dimensional Speckle-Tracking Echocardiography
por: Takase, Yoshiyuki, et al.
Publicado: (2018)

A selective detection of lysophosphatidylcholine in dried blood spots for diagnosis of adrenoleukodystrophy by LC-MS/MS
por: Mashima, Ryuichi, et al.
Publicado: (2016)

A Neonate with Mucopolysaccharidosis Type VII with Intractable Ascites
por: Fukui, Kana, et al.
Publicado: (2023)

Clinical Presentation of Mucopolysaccharidosis Type II (Hunter's Syndrome)
por: Chinawa, JM, et al.
Publicado: (2012)

Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
por: Link, Bianca, et al.
Publicado: (2010)

Structural Basis of Mucopolysaccharidosis Type II and Construction of a Database of Mutant Iduronate 2-Sulfatases
por: Saito, Seiji, et al.
Publicado: (2016)

Carpal Tunnel Syndrome in the Setting of Mucopolysaccharidosis II (Hunter Syndrome)
por: Argenta, Anne E., et al.
Publicado: (2017)

Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland
por: Żuber, Zbigniew, et al.
Publicado: (2023)

A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II
por: Sonoda, Hiroyuki, et al.
Publicado: (2018)

Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I
por: Nestrasil, Igor, et al.
Publicado: (2017)

A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation
por: Mashima, Ryuichi, et al.
Publicado: (2023)

Clinical characteristics and surgical history of Taiwanese patients with mucopolysaccharidosis type II: data from the hunter outcome survey (HOS)
por: Lin, Hsiang-Yu, et al.
Publicado: (2018)

Can serial cerebral MRIs predict the neuronopathic phenotype of MPS II?
por: Vollebregt, Audrey A. M., et al.
Publicado: (2021)

Genotype‐phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry
por: Clarke, Lorne A., et al.
Publicado: (2019)

Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
por: Barone, Rita, et al.
Publicado: (2018)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
por: Raluy-Callado, Mireia, et al.
Publicado: (2013)

Automated urinary sediment detection for Fabry disease using deep-learning algorithms
por: Uryu, Hidetaka, et al.
Publicado: (2022)

Burden of caregivers of patients with neuronopathic and non-neuronopathic Gaucher disease in Japan: A survey-based study
por: Koto, Yuta, et al.
Publicado: (2023)

Enhanced osteoblastic differentiation of parietal bone in a novel murine model of mucopolysaccharidosis type II
por: Yamazaki, Narutoshi, et al.
Publicado: (2023)

Atypical clinical presentation of mucopolysaccharidosis type II (Hunter syndrome): a case report
por: Shah, Gauri Shankar, et al.
Publicado: (2010)

Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome
por: Chiong, Mary Anne D., et al.
Publicado: (2017)

Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
por: Whiteman, David AH, et al.
Publicado: (2017)

Cochlear Implantation via the Transmeatal Approach in an Adolescent with Hunter Syndrome—Type II Mucopolysaccharidosis
por: Kim, Hantai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f3k5k4ehl3qjurfu97gknmce6n